Section Arrow
Quote
CVKD.NASDAQ
- Cadrenal Therapeutics Inc
Quotes are at least 15-min delayed:2026/03/06 20:43 EST
Regular Hours
Last
 8.18
+0.27 (+3.41%)
Day High 
8.305 
Prev. Close
7.91 
1-M High
8.96 
Volume 
16.09K 
Bid
7.85
Ask
8.35
Day Low
7.8299 
Open
7.89 
1-M Low
4.91 
Market Cap 
18.49M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 7.99 
20-SMA 6.79 
50-SMA 7.16 
52-W High 20.39 
52-W Low 4.91 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.72/-2.36
Enterprise Value
18.49M
Balance Sheet
Book Value Per Share
1.17
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
DAWNDay One Biopharmaceuticals21.21+8.44+66.09%-- 
IOVAIovance Biotherapeutics5.135+0.54+11.75%-- 
QNCXQuince Therapeutics0.1023-0.0025-2.39%-- 
EDSAEdesa Biotech6.53+2.92+80.89%-- 
IBRXImmunityBio8.65-0.3001-3.35%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.